Please login to the form below

Not currently logged in
Email:
Password:

IRX Therapeutics appoints Luba Greenwood to its board

She recently served as venture partner at Colt Ventures

Clinical-stage company IRX Therapeutics has appointed Luba Greenwood to its board of directors.

Her career has seen her gain significant pharmaceutical and biotechnology industry expertise, including building technology companies and providing strategic counsel to corporations.

Mark Leuchtenberger, president and chief executive officer, IRX Therapeutics, said: “Luba is a proven and respected leader in the life science sector.

“She has excelled as an investor, business development professional, lawyer and corporate strategist.”

Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations.

Greenwood most recently served as venture partner at Colt Ventures, and led business development strategy for Pronutria.

Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

She said: “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumour microenvironment with IRX-2.”

6th December 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics